Entity
Description
  • Value proposition

    Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons !

    One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission of Pixium Vision.

    Two novel life changing Bionic Vision Systems developed, with active implantable prostheses, that are intended to compensate for vision loss and blindness from retinal degeneration, like Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling to regain partial central visual perception and lead more independent lives.

    Advances in neuro-ophthalmology, innovative state of the art biomedical / bioelectronic technologies, smart bio-inspired bio-mimetic algorithms and AI, and miniaturization of micro/nano-electronics, enable minimal invasive retinal surgery, and develop systems that could provide blind people with a form of prosthetic bionic vision.

    • PRIMA (Subretinal) a miniaturized wireless photovoltaic implant platform initially for Dry-AMD. The company is conducting first-in-human feasibility trials in Europe and the US.
    • IRIS®II (Epiretinal) its first System for RP, equipped with a bio-inspired camera, an implant with 150 electrodes, designed to be explantable.

    Formed in Dec 2011, a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. Listed on Euronext Paris stock exchange in June 2014. Collaborates with a global ecosystem of scientific and clinical partners spanning the prestigious Vision research institutions including: Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona.

    twitter: @PixiumVision

    Ophthalmology, Retina, Bionic Vision, Neuromodulation, Neuroscience, Neurobiology, Artificial Vision, Neuro Opthalmology, Bio hacking, Neuro Ophthalmodulation, Artificial Vision, retinitis pigmentosa, blindness, ophtalmologie, vision restoration, bio electric, Age related Macular Degeneration AMD, bio electronic medicine, Digital Medicine, Sensory Neuromodulation, Bbioelectronics, and Dry AMD

  • Original language

    Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons !

    One must remember the notion that restoring some vision to those who have lost their sight is possible, has long been thought to be fanciful. However, we are in the Age of Neural Prostheses, Bioelectronics, and BMI. At frontier of neuroscience, interfacing the worlds of eye and the brain – “from Photons to Neurons”. Such is the breadth and depth of knowledge needed to build a world of bionic vision for those with vision loss. This is the mission of Pixium Vision.

    Two novel life changing Bionic Vision Systems developed, with active implantable prostheses, that are intended to compensate for vision loss and blindness from retinal degeneration, like Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), enabling to regain partial central visual perception and lead more independent lives.

    Advances in neuro-ophthalmology, innovative state of the art biomedical / bioelectronic technologies, smart bio-inspired bio-mimetic algorithms and AI, and miniaturization of micro/nano-electronics, enable minimal invasive retinal surgery, and develop systems that could provide blind people with a form of prosthetic bionic vision.

    • PRIMA (Subretinal) a miniaturized wireless photovoltaic implant platform initially for Dry-AMD. The company is conducting first-in-human feasibility trials in Europe and the US.
    • IRIS®II (Epiretinal) its first System for RP, equipped with a bio-inspired camera, an implant with 150 electrodes, designed to be explantable.

    Formed in Dec 2011, a bioelectronics technology company specialized in neuromodulation to restore a form of prosthetic vision to compensate for blindness. Listed on Euronext Paris stock exchange in June 2014. Collaborates with a global ecosystem of scientific and clinical partners spanning the prestigious Vision research institutions including: Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona.

    twitter: @PixiumVision

Corporate interactions BETA
Corporate TypeTweets Articles
Banque des Territoires Banque des Territoires
Bank, Banking
Other

8 Feb 2020


Euronext
Euronext
Finance, Financial Services
Euronext
Finance, Financial Services
Not capitalistic
Not partnership
Event

18 Jun 2014


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Not capitalistic
Not partnership
Event

10 Oct 2019


L'Oréal
L'Oréal
Cosmetics, Personal Care Product Manufacturing
L'Oréal
Cosmetics, Personal Care Product Manufacturing
Not capitalistic
Not partnership
Event

26 Sep 2016


Societe Generale
Societe Generale
Bank, Banking
Societe Generale
Bank, Banking
Other

6 Apr 2016


Fondation Adolphe de Rothschild
Fondation Adolphe de Rothschild
NGO, Think Tank, Hospitals and Health Care
Fondation Adolphe de Rothschild
NGO, Think Tank, Hospitals and Health Care
Not capitalistic
Not partnership
Event

22 Nov 2018


Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Not capitalistic
Partnership
Not event

29 Sep 2023


Similar entities
Loading...
Loading...
Social network dynamics